Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Single-Arm Phase I/IIa Study to Evaluate the Safety of Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte in Patients With Aging Frailty

NCT06063590 is registered in ClinicalTrials.gov with Cellcolabs Clinical SPV Limited as lead sponsor.

NCT NCT06063590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06063590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Single-Arm Phase I/IIa Study to Evaluate the Safety of Human Allogenic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte in Patients With Aging Frailty
Lead sponsor
Cellcolabs Clinical SPV Limited
Phase
Phase 1/2
Overall status
Completed
Start date
January 22, 2024
Completion date
August 28, 2025
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aging frailty